Treatment for methamphetamine cardiovascular disease

Abstract

A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The H2S donor may be one of sodium sulfide, diallyl trisulfide, diallyl disulfide, allicin, sugammadex, sulfanilamide, disulfiram, sulfonamide, sulfonates, sulfoxides, persulfides, polysulfides, and sulfones. The H2S donor may be sugammadex. The H2S donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.

Dependencies are inferred from the claim text.